Dexmedetomidine을 투여한 내과중환자실 환자의 심혈관계 부작용 발생률과 위험인자 분석
Incidence and Risk Factors for Dexmedetomidine-Associated Cardiovascular Adverse Effects in Intensive Care Unit Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Dexmedetomidine is a selective α2 agonist with sedative, analgesic, and sympatholytic properties. Dexmedetomidine has cardiovascular risks such as hypotension and bradycardia. For this reason, the U.S. Food and Drug Administration (FDA) recommends the short-term use of dexmedetomidine less than 24 hours. Therefore, this study was aimed at analyzing the current status and risk factors of the cardiovascular side effects of dexmedetomidine. Methods : A retrospective chart review of all adult critically ill patients in the medical intensive care units who received dexmedetomidine from January 2016 to May 2017 was performed. The incidence, risk factors and prognosis of the cardiovascular adverse effects were analyzed. Results : The total number of patients was 135, and the mean hours of dexmedetomidine administration was 165 hours. A total of 102 patients (75.6%) developed cardiovascular side effects. Among them, hypotension occurred in 99 patients (73.3%), of which 53 patients (53.5%) developed hypotension within 24 hours. Bradycardia occurred in eight patients (5.9%), of which two patients (25.0%) developed bradycardia within 24 hours. Multivariate analysis of the risk factors for hypotension showed an association between hypotension and low baseline mean arterial pressure (MAP)(p=0.028), patients with acute respiratory distress syndrome (ARDS)(p=0.030) and those given norepinephrine (p=0.017). The incidence of hypotension was lower in patients with underlying hypertension (p=0.030). Univariate analysis of the risk factors for bradycardia showed that the incidence of bradycardia was higher in patients with lower baseline heart rates (p=0.033), higher body weight (p=0.008), and those undergoing hemodialysis (p=0.009). Also, there were no significant differences in the days of mechanical ventilation, the number of hospital days, and the mortality rate in patients with hypotension or bradycardia. Conclusion : Dexmedetomidine was associated with a higher incidence of cardiovascular side effects. Specifically, patients who were diagnosed with lower MAP, ARDS, or in combination with norepinephrine use were more likely to develop hypotension. Therefore, it is necessary to closely monitor cardiovascular adverse effects in patients with these risk factors.
Abstract
Background : Dexmedetomidine is a selective α2 agonist with sedative, analgesic, and sympatholytic properties. Dexmedetomidine has cardiovascular risks such as hypotension and bradycardia. For this reason, the U.S. Food and Drug Administration (FDA) recommends the short-term use of dexmedetomidine less than 24 hours. Therefore, this study was aimed at analyzing the current status and risk factors of the cardiovascular side effects of dexmedetomidine. Methods : A retrospective chart review of all adult critically ill patients in the medical intensive care units who received dexmedetomidine from January 2016 to May 2017 was performed. The incidence, risk factors and prognosis of the cardiovascular adverse effects were analyzed. Results : The total number of patients was 135, and the mean hours of dexmedetomidine administration was 165 hours. A total of 102 patients (75.6%) developed cardiovascular side effects. Among them, hypotension occurred in 99 patients (73.3%), of which 53 patients (53.5%) developed hypotension within 24 hours. Bradycardia occurred in eight patients (5.9%), of which two patients (25.0%) developed bradycardia within 24 hours. Multivariate analysis of the risk factors for hypotension showed an association between hypotension and low baseline mean arterial pressure (MAP)(p=0.028), patients with acute respiratory distress syndrome (ARDS)(p=0.030) and those given norepinephrine (p=0.017). The incidence of hypotension was lower in patients with underlying hypertension (p=0.030). Univariate analysis of the risk factors for bradycardia showed that the incidence of bradycardia was higher in patients with lower baseline heart rates (p=0.033), higher body weight (p=0.008), and those undergoing hemodialysis (p=0.009). Also, there were no significant differences in the days of mechanical ventilation, the number of hospital days, and the mortality rate in patients with hypotension or bradycardia. Conclusion : Dexmedetomidine was associated with a higher incidence of cardiovascular side effects. Specifically, patients who were diagnosed with lower MAP, ARDS, or in combination with norepinephrine use were more likely to develop hypotension. Therefore, it is necessary to closely monitor cardiovascular adverse effects in patients with these risk factors.
참고문헌 (21)
- Desbiens NA, "Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment", Crit Care Med, 24(12), pp.1953~1961 (1996)
- Friese RS, "Sleep and recovery from critical illness and injury : a review of theory, current practice, and future directions", Crit Care Med, 36(3), pp.697~705 (2008)
- Barr J, "Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit", Crit Care Med, 41(1), pp.263~306 (2013)
- Devlin JW, "Pharmacology of commonly used analgesics and sedatives in the ICU : benzodiazepines, propofol, and opioids", Anesthesiol Clin, 29(4), pp.567~585 (2011)
- Weerink MAS, "Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine", Clin Pharmacokinet, 56(8), pp.893~913 (2017)
- Wunsch H, "Use of intravenous infusion sedation among mechanically ventilated patients in the United States", Crit Care Med, 37(12), pp.3031~3039 (2009)
- Nguyen D, "Ventilatory effects of dexmedetomidine, atipamezole, and isoflurane in dogs", Anesthesiology, 76(4), pp.573~579 (1992)
- Riker RR, "Dexmedetomidine vs midazolam for sedation of critically ill patients : a randomized trial", JAMA, 301(5), pp.489~499 (2009)
- Chrysostomou C, "Dexmedetomidine : sedation, analgesia and beyond", Expert Opin Drug Metab Toxicol, 4(5), pp.619~627 (2008)
- Ebert TJ, "The effects of increasing plasma concentrations of dexmedetomidine in humans", Anesthesiology, 93(2), pp.382~394 (2000)
- Maldonado JR, "Delirium in the acute care setting : characteristics, diagnosis and treatment", Crit Care Clin, 24(4), pp.657~722 (2008)
- Ely EW, "Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit", JAMA, 291(14), pp.1753~1762 (2004)
- Gerlach AT, "A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients", J Crit Care, 24(4), pp.568~574 (2009)
- Devabhakthuni S, "Evaluation of dexmedetomidine : safety and clinical outcomes in critically ill trauma patients", J Trauma, 71(5), pp.1164~1171 (2011)
- Silva Júnior GB, "Risk factors for death among critically ill patients with acute renal failure", Sao Paulo Med J, 124(5), pp.257~263 (2006)
- Alves GC, "Risk factors for death among critically ill elderly patients", Rev Bras Ter Intensiva, 22(2), pp.138~143 (2010)
- Gerlach AT, "Dexmedetomidine : an updated review", Ann Pharmacother, 41(2), pp.245~252 (2007)
- Gerlach AT, "Predictors of dexmedetomidine‑associated hypotension in critically ill patients", Int J Crit Illn Inj Sci, 6(3), pp.109~114 (2016)
- Kao KC, "Survival predictor in patients with acute respiratory distress syndrome and diffuse alveolar damage undergoing open lung biopsy", PLoS One, 12(7), pp.e0180018~ (2017)
- Hudson LD, "Clinical risks for development of the acute respiratory distress syndrome", Am J Respir Crit Care Med, 151, pp.293~301 (1995)
- Uhle F, "Pathophysiology of Sepsis", Anasthesiol Intensivmed Notfallmed Schmerzther, 50(2), pp.114~122 (2015)